{
    "Clinical Trial ID": "NCT00513292",
    "Intervention": [
        "INTERVENTION 1: ",
        "  FEC-75 Then Paclitaxel/Trastuzumab",
        "  Patients receive Fluorouracil, epirubicin, and cyclophosphamide (FEC) comprising fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies",
        "INTERVENTION 2: ",
        "  Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75",
        "  Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Diagnosis of invasive adenocarcinoma by core needle biopsy",
        "  Fine needle aspiration allowed provided primary tumor size < 2 cm and lymph node metastases are present",
        "  Excisional biopsy of the primary tumor allowed provided biopsy-positive lymph nodes are present",
        "  Primary tumor  2 cm and/or  1 biopsy-positive lymph node",
        "  HER2-positive disease",
        "  Confirmation by fluorescent in situ hybridization (FISH) requires gene amplification",
        "  Confirmation by immunohistochemistry (IHC) requires a strongly positive (3+) staining intensity score",
        "  Ductal carcinoma in situ (DCIS) or synchronous DCIS of the contralateral breast regardless of prior therapy allowed",
        "  Synchronous invasive breast cancer not allowed",
        "  Ipsilateral DCIS treated by local excision with or without hormonal therapy allowed",
        "  Those treated with radiation therapy are not allowed",
        "  No definitive clinical or radiologic evidence of metastatic disease",
        "  No history of invasive breast cancer",
        "  Hormone receptor status known",
        "  Menopausal status not specified",
        "  ECOG performance status of 0 -1",
        "  Absolute neutrophil count  1,200/mm\u00b3",
        "  Platelet count  100,000/mm\u00b3",
        "  Total bilirubin normal unless the patient has a grade 1 bilirubin elevation (normal to 1.5 times upper limit of normal [ULN]) resulting from Gilbert disease or similar syndrome due to slow conjugation of bilirubin",
        "  Alkaline phosphatase  2.5 times ULN",
        "  AST  1.5 times ULN",
        "  Creatinine normal",
        "  Left ventricular ejection fraction (LVEF)  55 by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) within the past 3 months",
        "  Patients with either skeletal pain or alkaline phosphatase that is > ULN but  2.5 times ULN allowed if bone scans fail to demonstrate metastatic disease",
        "  Suspicious findings on bone scan must be confirmed as benign by x-ray, MRI, or biopsy",
        "  Prior non-breast malignancies allowed if disease-free for 5 years since completion of initial treatment regimen and deemed by their physician to be at low risk for recurrence",
        "  Patients who had the following cancers are eligible if diagnosed and treated within the past 5 years:",
        "  Carcinoma in situ of the cervix",
        "  Colon carcinoma in situ",
        "  Melanoma in situ",
        "  Basal cell and squamous cell carcinoma of the skin",
        "  No cardiac disease that would preclude the use of epirubicin hydrochloride or trastuzumab (Herceptin\u00ae) including any of the following:",
        "  Active cardiac disease",
        "  Angina pectoris that requires the use of antianginal medication",
        "  Cardiac arrhythmia requiring medication",
        "  Severe conduction abnormality",
        "  Clinically significant valvular disease",
        "  Cardiomegaly on chest x-ray",
        "  Ventricular hypertrophy on EKG",
        "  Patient's with poorly controlled hypertension ( i.e., diastolic greater than 100 mm/Hg)",
        "  Patients with hypertension that is well controlled on medication are eligible",
        "  History of cardiac disease",
        "  Myocardial infarction documented as a clinical diagnosis or by EKG or any other tests",
        "  Documented congestive heart failure",
        "  Documented cardiomyopathy",
        "  No sensory or motor neuropathy  grade 2, as defined by the NCI's CTCAE v3.0",
        "  Women of reproductive potential must agree to use an effective non-hormonal method of contraception during therapy",
        "  Women of child bearing potential must have a negative urine or serum pregnancy test within 2 weeks of registration",
        "  Not pregnant or nursing",
        "  No psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements",
        "  No non-malignant systemic disease (e.g., cardiovascular, renal, hepatic) that would preclude treatment with either of the treatment regimens",
        "  No prior surgical axillary staging procedure",
        "  Prior non-excisional biopsy of an axillary node allowed",
        "  No prior treatment for this breast cancer",
        "  Hormonal therapy allowed if had been given for up to a total of 28 days anytime after diagnosis and before study entry",
        "  Hormonal therapy must stop at or before study entry and be re-started, if indicated, following surgery",
        "  No prior therapy with anthracyclines or taxanes for any malignancy",
        "  No other investigational agents within the past 30 days",
        "  No concurrent sex hormonal therapy (e.g., birth control pills, ovarian hormonal replacement therapy)",
        "  No concurrent therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulator (SERM), either for osteoporosis or breast cancer prevention"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  pCR Within the Breast, Defined as no Evidence of Invasive Tumor Remaining in the Breast at Surgery Following Completion of Chemotherapy",
        "  Pathological complete response (pCR) rates will be based on institutional pathology reports. In the final analysis for publication, rates will be based on blinded central review of these institutional pathology reports. The Chi-squared test will be conducted at the two-sided 0.05 level. A 95% confidence interval will be computed for the difference in pCR rates.",
        "  Time frame: Up to 5 years",
        "Results 1: ",
        "  Arm/Group Title: FEC-75 Then Paclitaxel/Trastuzumab",
        "  Arm/Group Description: Patients receive Fluorouracil, epirubicin, and cyclophosphamide (FEC) comprising fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies",
        "  Overall Number of Participants Analyzed: 138",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  56.5        (47.8 to 64.9)",
        "Results 2: ",
        "  Arm/Group Title: Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75",
        "  Arm/Group Description: Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies",
        "  Overall Number of Participants Analyzed: 142",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  54.2        (45.7 to 62.6)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 19/138 (13.77%)",
        "  Blood disorder 1/138 (0.72%)",
        "  Febrile neutropenia 1/138 (0.72%)",
        "  Hemoglobin decreased 8/138 (5.80%)",
        "  Hemolysis 0/138 (0.00%)",
        "  Atrial fibrillation 0/138 (0.00%)",
        "  Left ventricular failure 3/138 (2.17%)",
        "  Myocardial ischemia 0/138 (0.00%)",
        "  Sinus tachycardia 1/138 (0.72%)",
        "  Supraventricular tachycardia 0/138 (0.00%)",
        "  Extraocular muscle paresis 0/138 (0.00%)",
        "Adverse Events 2:",
        "  Total: 26/142 (18.31%)",
        "  Blood disorder 1/142 (0.70%)",
        "  Febrile neutropenia 3/142 (2.11%)",
        "  Hemoglobin decreased 11/142 (7.75%)",
        "  Hemolysis 1/142 (0.70%)",
        "  Atrial fibrillation 1/142 (0.70%)",
        "  Left ventricular failure 5/142 (3.52%)",
        "  Myocardial ischemia 1/142 (0.70%)",
        "  Sinus tachycardia 1/142 (0.70%)",
        "  Supraventricular tachycardia 1/142 (0.70%)",
        "  Extraocular muscle paresis 1/142 (0.70%)"
    ]
}